What question did this study set out to answer?

This study aims to compare anti Xa results from different commercially available assays in patients receiving low molecular weight heparin or danaparoid.

January 1, 1999Thrombosis and Haemostasis

Anti Xa Monitoring during Treatment with Low Molecular Weight Heparin or Danaparoid: Inter-assay Variability

View Full Paper

Ask AI

Bookmark

Why the study?

Is there significant inter-assay variability in anti Xa activity results among patients treated with low molecular weight heparin or danaparoid?

Population

Patients receiving either therapeutic or prophylactic low molecular weight heparin or danaparoid

Comparison

Measurement of anti Xa activity using eight… vs Comparison between the different anti Xa…

Design

Cross-sectional

Authors

RIRomina IampietroNational Institute for Biological Standards and Control AWAnita WoolleySheffield Teaching Hospitals NHS Foundation Trust FPF E PrestonGoethe University Frankfurt

Discussion

Member takes

Implication

Variability across anti-Xa assays may drive inconsistent LMWH dosing; leaves open whether standardization affects clinical outcomes.

Key Points

This study aims to compare anti Xa results from different commercially available assays in patients receiving low molecular weight heparin or danaparoid.
Compared eight anti Xa activity assays (five chromogenic, three clotting based) in patient samples.
Analyzed results from patients receiving enoxaparin, dalteparin, or danaparoid for either therapeutic or prophylactic purposes.
Evaluated the performance of the Heptest clotting assay against other techniques.
Mean anti Xa activity for enoxaparin was 0.28 to 0.64 iu/ml and for dalteparin was 0.43 to 0.69 iu/ml.
Heptest results were lower than other assays, influencing dose requirements for therapeutic range.
Danaparoid clotting assays showed mean results of 0.30 to 0.36 u/ml compared to 0.47 to 0.65 u/ml for chromogenic assays.

Structured PICO

Is there significant inter-assay variability in anti Xa activity results among patients treated with low molecular weight heparin or danaparoid?

Population

Patients receiving either therapeutic or prophylactic low molecular weight heparin (enoxaparin or dalteparin) or danaparoid (for heparin induced thrombocytopaenia)

Intervention

Measurement of anti Xa activity using eight different commercially available assays (five chromogenic and three clotting based)

Comparator

Comparison between the different anti Xa activity assays

Outcome

Anti Xa activity levelssurrogate

Significant inter-assay variability exists in anti-Xa monitoring for LMWH and danaparoid, which could lead to inappropriate dosing and increased bleeding risk if target ranges are not assay-specific.

Cite This Study

Iampietro et al. (1999) studied this question.

synapsesocial.com/papers/6a6f24cd5d37378ac1dc370d https://doi.org/10.1055/s-0037-1614377

View Full Paper

Ask AI

Bookmark

Anti Xa Monitoring during Treatment with Low Molecular Weight Heparin or Danaparoid: Inter-assay Variability

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Anti Xa Monitoring during Treatment with Low Molecular Weight Heparin or Danaparoid: Inter-assay Variability

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider